Cell and Gene Therapies Present Challenges to Payers
Formulary Watch, Tasmina Hydery and Milda Kaitz
With eight cell and gene therapies currently on the market — and several FDA decisions on other therapies expected later this year — concerns about how to provide patient access and insurance coverage are rising. A growing pipeline of cell and gene therapies that address more than 100 diseases has payers taking notice, often earlier in development to begin planning for these high-cost treatments.
For the full article, please visit Formulary Watch.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.